MA30780B1 - Composes et procedes associes a des agents etiquetes 18f - Google Patents

Composes et procedes associes a des agents etiquetes 18f

Info

Publication number
MA30780B1
MA30780B1 MA31764A MA31764A MA30780B1 MA 30780 B1 MA30780 B1 MA 30780B1 MA 31764 A MA31764 A MA 31764A MA 31764 A MA31764 A MA 31764A MA 30780 B1 MA30780 B1 MA 30780B1
Authority
MA
Morocco
Prior art keywords
compounds
methods associated
label agents
label
agents
Prior art date
Application number
MA31764A
Other languages
English (en)
Inventor
Lutz Lehmann
Ananth Srinivasan
Thomas Brumby
Detlev Suelzle
Timo Stellfeld
Keith Graham
Mylene Karramkam
Simon Ametamey
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP06090166A external-priority patent/EP1897885A1/fr
Priority claimed from EP07090079A external-priority patent/EP1985624A3/fr
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of MA30780B1 publication Critical patent/MA30780B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/655—Somatostatins
    • C07K14/6555—Somatostatins at least 1 amino acid in D-form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57545—Neuropeptide Y

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Optics & Photonics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

LA PRÉSENTE INVENTION CONCERNE DE NOUVEAUX COMPOSÉS ADAPTÉS POUR ÊTRE RADIO-ÉTIQUETÉS 18F OU DÉJÀ RADIO-ÉTIQUETÉS 18F, DES PROCÉDÉS DE FABRICATION DESDITS COMPOSÉS ET L'UTILISATION DESDITS COMPOSÉS DANS L'IMAGERIE DE DIAGNOSTIC. LESDITS COMPOSÉS ÉTIQUETÉS SE CARACTÉRISENT PAR LA FORMULE II DANS LAQUELLE LES SUBSTITUANTS G, Q, L, Y ET U SONT TELS QUE DÉFINIS DANS LES SPÉCIFICATIONS ET LES REVENDICATIONS.
MA31764A 2006-09-08 2009-04-06 Composes et procedes associes a des agents etiquetes 18f MA30780B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06090166A EP1897885A1 (fr) 2006-09-08 2006-09-08 Composés marqués au fluor et méthode pour la production
EP07090079A EP1985624A3 (fr) 2007-04-23 2007-04-23 Procédé simple de radiofluorination de composés actifs biologiquement ou de biomolécules

Publications (1)

Publication Number Publication Date
MA30780B1 true MA30780B1 (fr) 2009-10-01

Family

ID=39031005

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31764A MA30780B1 (fr) 2006-09-08 2009-04-06 Composes et procedes associes a des agents etiquetes 18f

Country Status (20)

Country Link
US (1) US8557776B2 (fr)
EP (5) EP3056509A1 (fr)
JP (2) JP5603074B2 (fr)
KR (1) KR20090058553A (fr)
AR (1) AR062726A1 (fr)
AU (1) AU2007294124A1 (fr)
BR (1) BRPI0716554A2 (fr)
CA (2) CA2662449A1 (fr)
CL (1) CL2007002620A1 (fr)
CO (1) CO6150196A2 (fr)
CR (1) CR10654A (fr)
IL (4) IL197363A0 (fr)
MA (1) MA30780B1 (fr)
MX (1) MX2009002492A (fr)
NO (1) NO20091428L (fr)
PE (1) PE20080850A1 (fr)
RU (1) RU2009112716A (fr)
TN (1) TN2009000063A1 (fr)
TW (1) TW200829277A (fr)
WO (1) WO2008028688A2 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2009002492A (es) 2006-09-08 2009-08-28 Bayer Schering Pharma Ag Agentes que comprenden compuestos marcados con 18f y metodos relacionados.
JP2010520229A (ja) * 2007-03-01 2010-06-10 バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト 放射性弗素化方法
GB201013808D0 (en) 2010-08-18 2010-09-29 Ge Healthcare Ltd Peptide radiotracer compositions
WO2012094334A1 (fr) * 2011-01-04 2012-07-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Marquage au 18f en une seule étape de substrats biologiques et utilisations desdits substrats biologiques marqués au 18f
JP2014526952A (ja) * 2011-06-09 2014-10-09 ジーイー・ヘルスケア・リミテッド 蒸留装置及び方法
PL2970345T3 (pl) * 2013-03-15 2019-12-31 Cancer Targeted Technology Llc Znakowane 18F środki do obrazowania PET ukierunkowane na PSMA
GB201314936D0 (en) 2013-08-21 2013-10-02 Ge Healthcare Ltd Radiolabelling method
GB201322456D0 (en) 2013-12-18 2014-02-05 Ge Healthcare Ltd Radiotracer compositions and methods
US11518754B2 (en) 2017-02-17 2022-12-06 Yale University Radiolabeled pharmaceuticals and methods of making and using same
JP7325341B2 (ja) 2017-07-11 2023-08-14 シンソークス，インク． 非天然ヌクレオチドの組み込み及びその方法
KR20240141853A (ko) 2017-08-03 2024-09-27 신톡스, 인크. 자가면역 질환의 치료를 위한 사이토카인 접합체
EP3781149A4 (fr) * 2018-04-20 2022-03-16 The General Hospital Corporation Promédicaments acétylés pour administration à travers la barrière hémato-encéphalique
EP3923974A4 (fr) 2019-02-06 2023-02-08 Synthorx, Inc. Conjugués d'il-2 et méthodes d'utilisation de ceux-ci
CN113150065B (zh) * 2021-03-11 2022-07-08 武汉英纳氏药业有限公司 一种合成肽及其应用
US20240277876A1 (en) * 2021-05-20 2024-08-22 The Regents Of The University Of California Pet imaging tracers
KR20250164815A (ko) 2023-03-31 2025-11-25 닛산 가가쿠 가부시키가이샤 피라졸 화합물 및 유해 생물 방제제

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5084555A (en) * 1989-08-21 1992-01-28 The Administrators Of The Tulane Educational Fund An octapeptide bombesin analog
WO1989002897A1 (fr) * 1987-09-24 1989-04-06 The Administrators Of The Tulane Educational Fund Peptides a usage therapeutique
US5723578A (en) * 1987-09-24 1998-03-03 The Administrators Of Tulane Educational Fund Peptide analogs of bombesin
MC2144A1 (fr) * 1988-10-14 1992-02-19 Univ Tulane Peptides therapeutiques
US5342755A (en) * 1989-06-02 1994-08-30 Georgetown University Method for the detection of anti-streptokinase antibodies
US6232071B1 (en) 1990-06-11 2001-05-15 Gilead Sciences, Inc. Tenascin-C nucleic acid ligands
US5244883A (en) 1990-11-29 1993-09-14 The Administrators Of The Tulane Educational Fund Nonapeptide bombesin antagonists
TW432073B (en) * 1995-12-28 2001-05-01 Pfizer Pyrazolopyridine compounds
WO1999033792A2 (fr) 1997-12-24 1999-07-08 Vertex Pharmaceuticals Incorporated Promedicaments des inhibiteurs de l'aspartyl-transferase
EA200000702A1 (ru) 1997-12-24 2000-12-25 Вертекс Фармасьютикалз Инкорпорейтед Пролекарства ингибиторов аспартилпротеаз
US6436989B1 (en) 1997-12-24 2002-08-20 Vertex Pharmaceuticals, Incorporated Prodrugs of aspartyl protease inhibitors
AU2012199A (en) 1997-12-24 1999-07-19 Vertex Pharmaceuticals Incorporated Prodrugs of aspartyl protease inhibitors
US6639076B1 (en) * 1998-08-18 2003-10-28 Eli Lilly And Company Growth hormone secretagogues
JP2003502314A (ja) 1999-06-14 2003-01-21 イーライ・リリー・アンド・カンパニー 化合物
WO2002044144A2 (fr) * 2000-11-30 2002-06-06 Advanced Research And Technology Institute, Inc. Utilisation de nucleophiles pour preparer des agents d'imagerie radiomarques, et composes associes
GB0115927D0 (en) * 2001-06-29 2001-08-22 Nycomed Amersham Plc Solid-phase nucleophilic fluorination
GB0206750D0 (en) 2002-03-22 2002-05-01 Amersham Plc Radiofluorination methods
US7396846B2 (en) 2002-04-09 2008-07-08 Eli Lilly And Company Growth hormone secretagogues
WO2004018502A1 (fr) * 2002-08-09 2004-03-04 Yamanouchi Europe B.V. Composes se liant a la p-selectine
US20080063599A1 (en) 2002-11-18 2008-03-13 Jorge Setoain Quinquer Compounds Which Can Be Used To Diagnose And Monitor Diseases Associated With The Formation Of Amyloid Protein Fibrils
WO2004073650A2 (fr) 2003-02-20 2004-09-02 University Of South Florida Inhibiteurs peptidomimetiques de l'activite de stat et utilisations de ceux-ci
GB0305704D0 (en) 2003-03-13 2003-04-16 Amersham Plc Radiofluorination methods
WO2006083424A2 (fr) 2004-12-28 2006-08-10 The Trustees Of Columbia University In The City Of New York Composes radiomarques et utilisations de ceux-ci
CA2617055A1 (fr) 2005-07-29 2007-02-08 Bayer Healthcare Llc Preparation et utilisation de derives aminoacides biphenyle pour traiter l'obesite
US20080029548A1 (en) 2006-05-05 2008-02-07 Ann De Wree Fabric treatment dispensing package
MX2009002492A (es) 2006-09-08 2009-08-28 Bayer Schering Pharma Ag Agentes que comprenden compuestos marcados con 18f y metodos relacionados.

Also Published As

Publication number Publication date
KR20090058553A (ko) 2009-06-09
AU2007294124A1 (en) 2008-03-13
IL211033A0 (en) 2011-04-28
TW200829277A (en) 2008-07-16
EP2063918B1 (fr) 2014-02-26
IL211527A0 (en) 2011-05-31
JP2010503618A (ja) 2010-02-04
JP5722966B2 (ja) 2015-05-27
EP2455105A3 (fr) 2012-09-05
BRPI0716554A2 (pt) 2013-09-24
EP3056509A1 (fr) 2016-08-17
EP2279759A3 (fr) 2013-04-17
CR10654A (es) 2009-04-14
JP5603074B2 (ja) 2014-10-08
EP2289564A2 (fr) 2011-03-02
EP2289564A3 (fr) 2012-11-14
EP2279759A2 (fr) 2011-02-02
WO2008028688A2 (fr) 2008-03-13
MX2009002492A (es) 2009-08-28
RU2009112716A (ru) 2010-10-20
NO20091428L (no) 2009-06-03
IL197363A0 (en) 2011-08-01
IL211526A0 (en) 2011-05-31
TN2009000063A1 (en) 2010-08-19
EP2455105A2 (fr) 2012-05-23
CA2858907A1 (fr) 2008-03-13
EP2063918A2 (fr) 2009-06-03
CA2662449A1 (fr) 2008-03-13
EP2455105B1 (fr) 2016-02-17
JP2014028813A (ja) 2014-02-13
WO2008028688A3 (fr) 2008-11-13
CO6150196A2 (es) 2010-04-20
US20080292548A1 (en) 2008-11-27
AR062726A1 (es) 2008-11-26
CL2007002620A1 (es) 2008-05-30
PE20080850A1 (es) 2008-09-02
US8557776B2 (en) 2013-10-15

Similar Documents

Publication Publication Date Title
MA30780B1 (fr) Composes et procedes associes a des agents etiquetes 18f
MA31690B1 (fr) Nouveaux fongicides
MA31597B1 (fr) Nouveaux herbicides
MA31596B1 (fr) Nouveaux herbicides
MA29549B1 (fr) Arylpyrazoles substitues destines a etre utilises contre des parasites
MA31989B1 (fr) Dérivés d'indolinone et procédés pour leur fabrication
EP1834571A4 (fr) Unite d'insertion pour endoscope
MA29816B1 (fr) Composes de benzimidazole thiophene
MA33275B1 (fr) Inhibiteurs de la replication du virus de l'immunodeficience humaine
MA31285B1 (fr) Dihydro et tetrahydro oxazolopyrimidinones substituees, preparation et utilisation de celles-ci
EP2232348A4 (fr) Diagnostic pour régulation d'écoulement massique
EP2921482A3 (fr) Inhibiteurs marqués de l'antigène membranaire spécifique de la prostate (PSMA), évaluation biologique, et utilisation en tant qu'agents d'imagerie
EP2092646A4 (fr) Synthèse d'interpolation numérique directe
EP1804794A4 (fr) Composes de spiropiperidine utilises comme inhibiteurs de beta-secretase en vue du traitement de la maladie d'alzheimer
EP1740559A4 (fr) Derives de phenyle 1,3,5-substitues utiles comme inhibiteurs de la beta-secretase pour le traitement de la maladie d'alzheimer
FR2919305B1 (fr) Vecteurs viraux adeno-associes pour l'expression de la dysferline.
MA30042B1 (fr) Composes calcilytiques
MA31623B1 (fr) Nouveaux herbicides
MA32985B1 (fr) Nouveaux microbiocides
MA48594B1 (fr) Nouveaux dérivés d'éther d'isoxazolyle en tant que pam alpha5 gaba a
MA30824B1 (fr) Radiofluration
MA28269A1 (fr) Arylpyrazoles substitués servant d'agents parasiticides
EP1746141A4 (fr) Composition d' epaississement
MA30331B1 (fr) ANTICORPS à EFGL 7 ET LEURS PROCEDES D'UTILISATION
EA200901142A1 (ru) 18f фторбензоильные меченые биологически активные соединения в качестве диагностических визуализирующих средств, а также бензотриазол-1-илоксибензоильные, 2,5-(диоксопирролидин-1-илокси)бензоильные и триметиламмониобензоильные предшественники